氯化锶[^(89)Sr]治疗转移性骨肿瘤致骨髓抑制的相关因素  

Related factors of myelosuppression induced by strontium-89 chloride treatment of bone metastases

作　　者：刘康其 周海中[1] Liu Kangqi;Zhou Haizhong(Department of Nuclear Medicine,Northern Jiangsu People's Hospital,Jiangsu Province,Yangzhou 225001,China)

机构地区：[1]江苏省苏北人民医院核医学科,扬州225001

出　　处：《国际放射医学核医学杂志》2022年第4期254-258,共5页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：氯化锶[^(89)Sr](以下简称“^(89)Sr”)是一种治疗转移性骨肿瘤尤其是全身多发性转移性骨肿瘤的放射性药物,但^(89)Sr致骨髓抑制的不良反应使其临床应用受到了一定的限制。除了^(89)Sr本身的放射生物效应外,^(89)Sr治疗时的骨肿瘤负荷,^(89)Sr治疗前的放疗、化疗以及抗雄激素治疗等都是引起骨髓抑制的重要因素。笔者对^(89)Sr治疗转移性骨肿瘤致骨髓抑制的相关因素进行综述。Strontium-89 chloride(hereinafter referred to as"^(89)Sr")is a radiopharmaceutical for the treatment of bone metastases,especially systemic multiple bone metastases,but its clinical application is limited due to the adverse effect of myelosuppression.In addition to the radiobiological effects of^(89)Sr itself,bone tumor burden during^(89)Sr treatment,radiotherapy,chemotherapy and antiandrogen therapy before^(89)Sr treatment are all important factors leading to myelosuppression.The authors review the related factors of myelosuppression induced by^(89)Sr treatment of bone metastases.

关 键 词：锶放射性同位素 骨肿瘤 肿瘤转移 骨髓抑制 

分 类 号：R738.1[医药卫生—肿瘤]